BEIJING KONRUNS PHARMACEUTICAL
Konruns Pharmaceutical is a manufacturing company. They produce special drugs for the medical and healthcare industries. Their drugs include CX1026, CX1003, and KC1036.
BEIJING KONRUNS PHARMACEUTICAL
Social Links:
Industry:
Biotechnology Manufacturing Medical Pharmaceutical
Founded:
2003-09-03
Status:
Active
Contact:
86-10-8289-8888
Email Addresses:
[email protected]
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta SPF Mobile Non Scaleable Content Nginx PHP PHP 7 China Ministry Of Public Security China Unicom Xinnet DNS
Similar Organizations
Beijing Jinhao Pharmaceutical Co.
Beijing Kinghawk Pharmaceutical specializes in biotech and pharmaceutical product development.
Bliss Gvs Pharma
Bliss Gvs Pharma is a pharmaceutical company that develops manufactures and market high-quality pharmaceutical products that are affordable.
Hainan Poly Pharm
Hainan Poly Pharm manufactures and distributes pharmaceutical products.
Jiangsu Wanbang Biochemical Pharmaceuticals Co. Ltd
Jiangsu Wanbang Biochemical Pharmaceuticals Co. Ltd. develops, manufactures, and distributes pharmaceutical products.
Mayinglong
Mayinglong Pharmaceutical Group manufactures and markets pharmaceutical products.
Pharos Indonesia
Pharos Indonesia is a pharmaceutical company which produces and sells pharmaceutical products.
Protech Biosystems
Protech Biosystems is a pharmaceutical company that develops, manufactures, and markets pharma products.
SHINPOONG.CO
Shinpoong Pharmaceutical Co., Ltd. Date established.
SOLA Pharmaceuticals
Sola Pharmaceuticals is a manufacturer and distributor of pharmaceutical products.
Zhejiang Ausun Pharmaceutical
Zhejiang Ausun Pharmaceutical manufactures and distributes pharmaceutical products.
Stock Details
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2020-12-07 | Nuance Biotech | Beijing Konruns Pharmaceutical investment in Series D - Nuance Biotech | 181 M USD |
| 2016-10-09 | Recomgen Biotech | Beijing Konruns Pharmaceutical investment in Series B - Recomgen Biotech | 20 M CNY |
More informations about "Beijing Konruns Pharmaceutical"
Beijing Konruns Pharmaceutical - Crunchbase
Konruns Pharmaceutical researches, manufactures, and distributes pharmaceutical products. ... 899 Number of Organizations • $301.5B Total Funding Amount • 2,014 Number of Investors. Track . Show More . IPO & …See details»
Beijing Konruns Pharmaceutical Co Ltd - Financial Times
Beijing Konruns Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research and development, production and sales of drugs. The Company's main product …See details»
603590.SS - | Stock Price & Latest News | Reuters
Nov 14, 2024 Beijing Konruns Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research and development, production and sales of drugs. ... the world's media …See details»
Beijing Konruns Pharmaceutical Company - PitchBook
Apr 22, 2019 Beijing Konruns Pharmaceutical Company General Information Description. Beijing Konruns Pharmaceutical Co Ltd is a Chinese pharmaceutical company. It is engaged in the research and development of innovative drugs, …See details»
Beijing Konruns Pharmaceutical Co.,Ltd. Company Description
Nov 1, 2024 Beijing Konruns Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceuticals in China and internationally. The …See details»
Beijing Konruns Pharmaceutical Co.,Ltd. (603590.SS)
Find the latest Beijing Konruns Pharmaceutical Co.,Ltd. (603590.SS) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
Beijing Konruns Pharmaceutical Co.,Ltd. Stock - MarketScreener.com
Jun 30, 2021 Beijing Konruns Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research and development, production and sales of drugs. The Company's …See details»
603590: Beijing Konruns Pharmaceutical Co.,Ltd. - Summary | Jitta
Beijing Konruns Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceuticals in China and internationally. The company offers agkistrodon …See details»
Beijing Konruns PharmaceuticalLtd SHSE:603590 Stock Report
Nov 10, 2024 Beijing Konruns Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceuticals in China and internationally. The …See details»
Beijing Konruns Pharmaceutical Co.,Ltd. (SHA: 603590) - Stock …
Oct 10, 2024 Beijing Konruns Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceuticals in China and internationally. The …See details»
Beijing Konruns Pharmaceutical Stock Price - Markets Insider
May 16, 2024 Beijing Konruns Pharmaceutical Co., Ltd. engages in the research, development, production and sales of pharmaceuticals. It produces freeze dried powder injection, raw …See details»
November 2024's Leading Growth Companies With Significant …
Overview: Beijing Konruns Pharmaceutical Co., Ltd. is involved in the research, development, production, and sale of pharmaceuticals both in China and internationally, with a market cap of …See details»
Beijing Konruns Pharmaceutical Co Ltd - Financial Times
Beijing Konruns Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research and development, production and sales of drugs. The Company's main product …See details»
Jincaopian Tablets - Drug Targets, Indications, Patents - Synapse
Nov 21, 2024 Jincaopian Tablets, Initially developed by Beijing Konruns Pharmaceutical Co., Ltd., Now, its global highest R&D status is Phase 3, Therapeutic Areas: Infectious …See details»
CX1003 in Advanced Solid Tumor - Clinical Trials Registry - ICH GCP
Sep 15, 2019 December 29, 2021 updated by: Beijing Konruns Pharmaceutical Co., Ltd. A Phase 1, Multicenter, Open-label, Dose Escalation/Expansion Study Evaluating the Safety, …See details»
603590 Stock Price Quote - Morningstar
Nov 22, 2024 Beijing Konruns Pharmaceutical Co Ltd Class A. Beijing Konruns Pharmaceutical Co Ltd Class A 603590. Stock XSHG Rating as of Nov 22, 2024. Summary; Chart; News; …See details»
Kanitinib in Solid Tumors - Clinical Trials Registry - ICH GCP
Aug 25, 2016 September 1, 2020 updated by: Beijing Konruns Pharmaceutical Co., Ltd. ... This is where you will find people and organizations involved with this study. Sponsor. Beijing …See details»
Beijing Konruns Pharmaceutical describes new KAT6A inhibitors
Oct 24, 2024 Beijing Konruns Pharmaceutical Co. Ltd. has identified histone acetyltransferase KAT6A (monocytic leukemia zinc finger protein; MOZ; MYST-3) inhibitors reported to be useful …See details»
November 2024's Leading Growth Companies With Significant …
4 days ago Beijing Konruns Pharmaceutical demonstrates potential as a growth company with expected annual earnings growth of 34.3%, surpassing the CN market's 26.2%. Despite this, …See details»